AI assistant
Alphabet Inc. — Director's Dealing 2023
Dec 5, 2023
29736_dirs_2023-12-05_2d08f723-c3f3-4caa-8c8c-cf637f91e711.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Verve Therapeutics, Inc. (VERV)
CIK: 0001840574
Period of Report: 2023-12-01
Reporting Person: GV 2023 GP, L.L.C. (Member of 10% Group)
Reporting Person: GV 2023 GP, L.P. (Member of 10% Group)
Reporting Person: GV 2023, L.P. (Member of 10% Group)
Reporting Person: Alphabet Inc. (Member of 10% Group)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1800000 | Indirect |
Footnotes
F1: The securities reported in this row are directly beneficially owned by GV 2023, L.P. (the "Partnership"). GV 2023 GP, L.P. (the "GP") is the general partner of the Partnership. GV 2023 GP, L.L.C. ("GV 2023 LLC") is the general partner of the GP. Alphabet Holdings LLC ("Alphabet Holdings") is the sole member of GV 2023 LLC. XXVI Holdings Inc. ("XXVI") is the sole member of Alphabet Holdings. Alphabet Inc. is the controlling stockholder of XXVI. Each of the GP, GV 2023 LLC, Alphabet Holdings, XXVI and Alphabet Inc. may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the securities directly beneficially owned by the Partnership. Each of the GP, GV 2023 LLC, Alphabet Holdings, XXVI, and Alphabet Inc. disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.